Drug name: Cirmtuzumab


Related CSCTT Targets

ROR1 [ref.1]Q01973

Cirmtuzumab

Cas.no PubChem ID
1643432-38-5 381127843
Known Target
ROR1Q01973
Introduction
Cirmtuzumab is a potentially first-in-class ROR1-targeted monoclonal antibody. Cirmtuzumab is designed to attach to ROR1, on the surface of chronic lymphocytic leukemia (CLL) cells to block cell growth and survival. ROR1 is rarely expressed on healthy cells so the idea is to preferentially get rid of the cancer cells.

Cirmtuzumab-Structure

...

Reference

  • [1] Inhibition of Chemotherapy Resistant Breast Cancer Stem Cells by a ROR1 Specific Antibody
    Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1370-1377.. [ 30622177 ]

Back to top